NCT02380079进行中（未招募）1 期
Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Invenux, LLC
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Determine the safety, tolerability, and dose limiting toxicities of escalating doses of SCD-101, assessed by frequency and severity of adverse events (AEs), and changes in vital signs, 12-lead ECGs and laboratory assessments as compared to baseline
研究概览
简要总结
The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.
详细描述
This is single site, dose- escalation study of SCD-101 in participants with homozygous sickle cell disease (S/S) or S/beta 0 Thalassemia. All participants will be monitored for safety, tolerability, and dose-limiting toxicities.
The study is divided into two parts. Part A is an open-label, non-randomized, non-placebo-controlled dose escalation study with a 28-day treatment phase and 14-day follow-up phase with five cohorts . Part B is a randomized, placebo-controlled, confirmatory 2x2 crossover cohort with a 28 day washout between periods, and a 28-day follow-up phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18-55 years of age
- •Homozygous sickle cell disease or S/beta 0 thalassemia
- •Hemoglobin F ≤10%
- •Hemoglobin ≥ 6.0 g/dL and ≤ 9.5 g/dL
- •Female participants of child bearing potential and male participants whose partner is a female of child bearing potential must be willing to use approved contraception during the trial and for 3 months following the end of treatment. Only barrier methods or complete abstinence are acceptable for this study. Participants using hormonal contraception (including morning-after-pill) and IUD are excluded unless willing/able to change to an acceptable form of contraception.
- •Ability to adhere to the study visit schedule and other protocol requirements
- •Ability to understand and the willingness to sign an informed consent document
排除标准
- •Red blood cell transfusion within 3 months of enrollment
- •Hydroxyurea treatment within 6 months of enrollment
- •Painful or other acute sickle cell event that required a hospitalization within 4-weeks of enrollment
- •AST and/or ALT >3x upper limit of normal and/or creatinine >2x upper limit of normal or any other significant renal or hepatic impairment
- •Estimated creatinine clearance (CrCl) < 60 mL/min (Cockcroft- Gault formula) at screening.
- •QTc interval of >470 msec at trial entry and participant with congenital long QT syndrome.
- •No other significant sickle cell or non-sickle cell illness that would confound the results of the trial
- •Any condition that, in the view of the investigator, places the participant at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial
- •Participant pregnant or nursing an infant or planning pregnancy during the course of the trial
- •History of allergic reactions attributed to sorghum or compounds of similar chemical or biologic composition (such as Nicosan, Niprisan, Jobelyn or Xickle).
- •Other investigational drug use within 3 months of enrollment
- •PROMIS Fatigue Questionnaire 8a T-score ˂ 44.3
研究组 & 干预措施
SCD-101
Experimental
SCD-101 dosed TID for 28-days
干预措施: SCD-101 (Drug)
Placebo
Placebo Comparator
Placebo dosed TID for 28-days
干预措施: SCD-101 (Drug)
结局指标
主要结局
Determine the safety, tolerability, and dose limiting toxicities of escalating doses of SCD-101, assessed by frequency and severity of adverse events (AEs), and changes in vital signs, 12-lead ECGs and laboratory assessments as compared to baseline
时间窗: From the time the participant is administered the first dose through the final follow-up (18 weeks)
次要结局
- Determine the effect of escalating doses of SCD-101 on the mean change from baseline in red blood cell hemolysis as measured by lactate dehydrogenase (LDH) and indirect bilirubin.(From the time the participant is accessed at baseline through the final follow-up (18 weeks))
- Determine the effect of escalating doses of SCD-101 on the mean change from baseline in the percent of venous circulating sickle red blood cells(From the time the participant is accessed at baseline through the final follow-up (18 weeks))
- Determine the effect of escalating doses of SCD-101 on the mean change from baseline in functional capacity as measured by the 6-Minute Walk Test(From the time the participant is accessed at baseline through the final follow-up (18 weeks))
- Determine the effect of escalating doses of SCD-101 on the mean change in hemoglobin form base line(From the time the participant is accessed at baseline through the final follow-up (18 weeks))
- Determine the effect of escalating doses of SCD-101 on the mean change from baseline in fatigue as measured by the PROMIS fatigue questionnaire(From the time the participant is accessed at baseline through the final follow-up (18 weeks))
- Determine the effect of escalating doses of SCD-101 on the mean change in percent reticulocytes from baseline(From the time the participant is accessed at baseline through the final follow-up (18 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) InfectionChronic Hepatitis CNCT00823862Dynavax Technologies Corporation34
招募中
1 期
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04472858Suzhou Zelgen Biopharmaceuticals Co.,Ltd30
招募中
1 期
Study SC-101 in Subjects With Advanced MalignanciesAdvanced Solid TumorNCT06220838Tianjin ConjuStar Biologics Co., Ltd.100
已完成
1 期
A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard TherapySolid TumorsNCT01159522SynCore Biotechnology Co., Ltd.33
招募中
1 期
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular CarcinomaHepatitis B Virus Related Hepatocellular CarcinomaHepatocellular Carcinoma RecurrentNCT05417932SCG Cell Therapy Pte. Ltd.46